iData Insights

Meiji Seika Pharma Co., Ltd. - Product Pipeline Review – 2015 Is Released

Press Release   •   Feb 05, 2016 16:27 IST

This report provides comprehensive information on the current therapeutic developmental pipeline of Meiji Seika Pharma Co., Ltd.s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Meiji Seika Pharma Co., Ltd. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Meiji Seika Pharma Co., Ltd.s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Meiji Seika Pharma Co., Ltd.s pipeline products Reasons to buy - Evaluate Meiji Seika Pharma Co., Ltd.s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Meiji Seika Pharma Co., Ltd. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Meiji Seika Pharma Co., Ltd. s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Meiji Seika Pharma Co., Ltd. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Meiji Seika Pharma Co., Ltd. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Meiji Seika Pharma Co., Ltd. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues

Browse Complete Report with TOC http://www.idatainsights.com/reports-landing-page.php?id=179138/meiji-seika-pharma-co-ltd-product-pipeline-review-2015

To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landing-page.php?id=179138/meiji-seika-pharma-co-ltd-product-pipeline-review-2015

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Meiji Seika Pharma Co., Ltd. Snapshot 5

Meiji Seika Pharma Co., Ltd. Overview 5

Key Information 5

Key Facts 5

Meiji Seika Pharma Co., Ltd. - Research and Development Overview 6

Key Therapeutic Areas 6

Meiji Seika Pharma Co., Ltd. - Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products - Monotherapy 9

Pipeline Products - Partnered Products 10

Partnered Products/Combination Treatment Modalities 11

Pipeline Products - Out-Licensed Products 12

Out-Licensed Products/Combination Treatment Modalities 13

Meiji Seika Pharma Co., Ltd. - Pipeline Products Glance 14

Meiji Seika Pharma Co., Ltd. - Late Stage Pipeline Products 14

Pre-Registration Products/Combination Treatment Modalities 14

Phase III Products/Combination Treatment Modalities 15

Meiji Seika Pharma Co., Ltd. - Clinical Stage Pipeline Products 16

Phase II Products/Combination Treatment Modalities 16

Phase I Products/Combination Treatment Modalities 17

Meiji Seika Pharma Co., Ltd. - Early Stage Pipeline Products 18

Preclinical Products/Combination Treatment Modalities 18

Meiji Seika Pharma Co., Ltd. - Drug Profiles 19

asenapine maleate 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

fluvoxamine maleate 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

ziprasidone mesylate 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

safinamide 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

ME-1111 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

mirtazapine ODT 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

talaporfin sodium 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

udenafil 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

arbekacin 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

trastuzumab biosimilar 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

CP-9531 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Meiji Seika Pharma Co., Ltd. - Pipeline Analysis 37

Meiji Seika Pharma Co., Ltd. - Pipeline Products by Target 37

Meiji Seika Pharma Co., Ltd. - Pipeline Products by Route of Administration 39

Meiji Seika Pharma Co., Ltd. - Pipeline Products by Molecule Type 40

Meiji Seika Pharma Co., Ltd. - Pipeline Products by Mechanism of Action 41

Meiji Seika Pharma Co., Ltd. - Recent Pipeline Updates 42

Meiji Seika Pharma Co., Ltd. - Dormant Projects 47

Meiji Seika Pharma Co., Ltd. - Discontinued Pipeline Products 48

Discontinued Pipeline Product Profiles 48

AM-831 48

ME-3738 48

Meiji Seika Pharma Co., Ltd. - Locations And Subsidiaries 49

Head Office 49

Other Locations & Subsidiaries 49

Appendix 50

Methodology 50

Coverage 50

Secondary Research 50

Primary Research 50

Expert Panel Validation 50

Contact Us 50

Disclaimer 51" width="80" height="40" />Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Meiji Seika Pharma Co., Ltd. Snapshot 5

Meiji Seika Pharma Co., Ltd. Overview 5

Key Information 5

Key Facts 5

Meiji Seika Pharma Co., Ltd. - Research and Development Overview 6

Key Therapeutic Areas 6

Meiji Seika Pharma Co., Ltd. - Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products - Monotherapy 9

Pipeline Products - Partnered Products 10

Partnered Products/Combination Treatment Modalities 11

Pipeline Products - Out-Licensed Products 12

Out-Licensed Products/Combination Treatment Modalities 13

Meiji Seika Pharma Co., Ltd. - Pipeline Products Glance 14

Meiji Seika Pharma Co., Ltd. - Late Stage Pipeline Products 14

Pre-Registration Products/Combination Treatment Modalities 14

Phase III Products/Combination Treatment Modalities 15

Meiji Seika Pharma Co., Ltd. - Clinical Stage Pipeline Products 16

Phase II Products/Combination Treatment Modalities 16

Phase I Products/Combination Treatment Modalities 17

Meiji Seika Pharma Co., Ltd. - Early Stage Pipeline Products 18

Preclinical Products/Combination Treatment Modalities 18

Meiji Seika Pharma Co., Ltd. - Drug Profiles 19

asenapine maleate 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

fluvoxamine maleate 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

ziprasidone mesylate 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

safinamide 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

ME-1111 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

mirtazapine ODT 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

talaporfin sodium 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

udenafil 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

arbekacin 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

trastuzumab biosimilar 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

CP-9531 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Meiji Seika Pharma Co., Ltd. - Pipeline Analysis 37

Meiji Seika Pharma Co., Ltd. - Pipeline Products by Target 37

Meiji Seika Pharma Co., Ltd. - Pipeline Products by Route of Administration 39

Meiji Seika Pharma Co., Ltd. - Pipeline Products by Molecule Type 40

Meiji Seika Pharma Co., Ltd. - Pipeline Products by Mechanism of Action 41

Meiji Seika Pharma Co., Ltd. - Recent Pipeline Updates 42

Meiji Seika Pharma Co., Ltd. - Dormant Projects 47

Meiji Seika Pharma Co., Ltd. - Discontinued Pipeline Products 48

Discontinued Pipeline Product Profiles 48

AM-831 48

ME-3738 48

Meiji Seika Pharma Co., Ltd. - Locations And Subsidiaries 49

Head Office 49

Other Locations & Subsidiaries 49

Appendix 50

Methodology 50

Coverage 50

Secondary Research 50

Primary Research 50

Expert Panel Validation 50

Contact Us 50

Disclaimer 51

Read More http://www.idatainsights.com/reports-landing-page.php?id=179138/meiji-seika-pharma-co-ltd-product-pipeline-review-2015

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

ContactUs:
iData Insights

Tel: 1-866-237-2965

Web: http://www.idatainsights.com
Email: info@idatainsights.com

AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.